Who
Celia Eckert
SVP, General Counsel
Company insider
Files Form 4 as: SVP, General Counsel, Xencor.
In numbers
- Trades disclosed
- 31
- Buys
- 0
- Sells
- 12
- Bought
- $0
- Sold
- $505K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 2 Mar 2020
- Last trade
- 6 Mar 2026
- Last filed
- 9 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 Mar 2026filed 9 Mar 2026 | XNCR XencorBiotechnology | SEC FORM 4 Sold | $19K1,767 at $11.02 | filing |
| 6 Mar 2026filed 9 Mar 2026 | XNCR XencorBiotechnology | SEC FORM 4 Sold | $19K1,767 at $11.02 | filing |
| 5 Mar 2026filed 9 Mar 2026 | XNCR XencorBiotechnology | SEC FORM 4 Sold | $36K3,244 at $11.25 | filing |
| 5 Mar 2026filed 9 Mar 2026 | XNCR XencorBiotechnology | SEC FORM 4 Sold | $36K3,244 at $11.25 | filing |
| 3 Mar 2026filed 4 Mar 2026 | XNCR XencorBiotechnology | SEC FORM 4 Sold | $18K1,492 at $11.90 | filing |
| 3 Mar 2026filed 4 Mar 2026 | XNCR XencorBiotechnology | SEC FORM 4 Sold | $18K1,492 at $11.90 | filing |
| 2 Mar 2026filed 4 Mar 2026 | XNCR XencorBiotechnology | SEC FORM 4 Code A | —18,680 at $0.00 | filing |
| 2 Mar 2026filed 4 Mar 2026 | XNCR Xencoroption or derivative · Biotechnology | SEC FORM 4 Code A | —112,080 at $0.00 | filing |
| 2 Mar 2026filed 4 Mar 2026 | XNCR Xencoroption or derivative · Biotechnology | SEC FORM 4 Code A | —112,080 at $0.00 | filing |
| 2 Mar 2026filed 4 Mar 2026 | XNCR XencorBiotechnology | SEC FORM 4 Code A | —18,680 at $0.00 | filing |
| 10 Mar 2025filed 11 Mar 2025 | XNCR XencorBiotechnology | SEC FORM 4 Sold | $78K5,740 at $13.60 | filing |
| 4 Mar 2025filed 5 Mar 2025 | XNCR Xencoroption or derivative · Biotechnology | SEC FORM 4 Code A | —65,847 at $0.00 | filing |
| 4 Mar 2025filed 5 Mar 2025 | XNCR XencorBiotechnology | SEC FORM 4 Code A | —21,949 at $0.00 | filing |
| 11 Mar 2024filed 12 Mar 2024 | XNCR XencorBiotechnology | SEC FORM 4 Sold | $20K850 at $23.50 | filing |
| 5 Mar 2024filed 7 Mar 2024 | XNCR Xencoroption or derivative · Biotechnology | SEC FORM 4 Code A | —78,534 at $0.00 | filing |
| 5 Mar 2024filed 7 Mar 2024 | XNCR XencorBiotechnology | SEC FORM 4 Sold | $91K3,892 at $23.43 | filing |
| 5 Mar 2024filed 7 Mar 2024 | XNCR XencorBiotechnology | SEC FORM 4 Code A | —13,089 at $0.00 | filing |
| 9 Mar 2023filed 13 Mar 2023 | XNCR XencorBiotechnology | SEC FORM 4 Sold | $21K711 at $29.88 | filing |
| 6 Mar 2023filed 8 Mar 2023 | XNCR XencorBiotechnology | SEC FORM 4 Sold | $77K2,462 at $31.42 | filing |
| 3 Mar 2023filed 6 Mar 2023 | XNCR XencorBiotechnology | SEC FORM 4 Sold | $13K427 at $31.54 | filing |
News
Analyzing Cardiff Oncology (NASDAQ:CRDF) and Xencor (NASDAQ:XNCR)XNCR · themarketsdaily.com · 21 Oct 2026
0 headlines in the last 90 days name Celia Eckert; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.